Twelves C J, Dobbs N A, Curnow A, Coleman R E, Stewart A L, Tyrrell C J, Canney P, Rubens R D
Imperial Cancer Research Fund Clinical Oncology Unit, UMDS, Guy's Hospital, London, UK.
Br J Cancer. 1994 Nov;70(5):990-3. doi: 10.1038/bjc.1994.435.
Thirty-four evaluable patients were treated with vinorelbine, a novel, semisynthetic vinca alkaloid, as first-line chemotherapy for advanced breast cancer. They received vinorelbine 25 mg m-2 i.v. given weekly for a maximum of 16 cycles. Two patients achieved a complete remission and 15 a partial remission, giving a response rate of 17/34 (50%; 95% CI of 34-66%); median response duration was 5.8 months. The median progression-free interval was 4.4 months and median survival 9.9 months. Treatment was generally well tolerated. Fatigue was the most common side-effect. The main reason for dose adjustments was myelosuppression; 68% of patients had WHO grade 3 or 4 neutropenia and there was one death attributed to neutropenic sepsis. Nausea/vomiting and neuropathy were mild and alopecia was uncommon. This study confirms vinorelbine as a highly active, well-tolerated agent in advanced breast cancer worthy of evaluation in combination chemotherapy regimens.
34例可评估患者接受了长春瑞滨治疗，长春瑞滨是一种新型半合成长春花生物碱，作为晚期乳腺癌的一线化疗药物。他们接受静脉注射长春瑞滨25mg/m²，每周一次，最多16个周期。2例患者完全缓解，15例部分缓解，缓解率为17/34（50%；95%可信区间为34%-66%）；中位缓解持续时间为5.8个月。中位无进展生存期为4.4个月，中位生存期为9.9个月。治疗一般耐受性良好。疲劳是最常见的副作用。剂量调整的主要原因是骨髓抑制；68%的患者出现世界卫生组织3级或4级中性粒细胞减少，有1例死于中性粒细胞减少性败血症。恶心/呕吐和神经病变较轻，脱发不常见。本研究证实长春瑞滨是一种在晚期乳腺癌中具有高活性、耐受性良好的药物，值得在联合化疗方案中进行评估。
